Cargando…

Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals

Streptococcus pneumoniae is the leading bacterial opportunistic infection in HIV-infected individuals. Anti-retroviral treatment (ART) of HIV-infected individuals reduces their risk of invasive pneumococcal disease (IPD), however, it remains 20- to 40-fold greater compared with age-matched general p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nunes, Marta C., Madhi, Shabir A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367711/ https://www.ncbi.nlm.nih.gov/pubmed/22426374 http://dx.doi.org/10.4161/hv.18432

Ejemplares similares

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV
por: Nunes, Marta C., et al.
Publicado: (2021)

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
por: Wilck, Marissa, et al.
Publicado: (2023)

Use of Multiplex Quantitative PCR To Evaluate the Impact of Pneumococcal Conjugate Vaccine on Nasopharyngeal Pneumococcal Colonization in African Children
por: Olwagen, Courtney P., et al.
Publicado: (2017)

Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status
por: Madhi, Shabir A., et al.
Publicado: (2017)

Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV-Exposed Uninfected Children: A Systematic Review and Meta-Analysis
por: Mutsaerts, Eleonora A.M.L., et al.
Publicado: (2018)

Immunogenicity of Seven-Valent Pneumococcal Conjugate Vaccine Administered at 6, 14 and 40 Weeks of Age in South African Infants
por: Jones, Stephanie A., et al.
Publicado: (2013)

Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data
por: Feng, Shuo, et al.
Publicado: (2023)

Immunogenicity and Efficacy of Pneumococcal Conjugate Vaccine (Prevenar13(®)) in Preventing Acquisition of Carriage of Pneumococcal Vaccine Serotypes in Tanzanian Children With HIV/AIDS
por: Makenga, Geofrey, et al.
Publicado: (2021)

Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults
por: Marra, Fawziah, et al.
Publicado: (2019)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV
por: Mohapi, Lerato, et al.
Publicado: (2022)

HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV)
por: Meiring, Susan, et al.
Publicado: (2016)

Vaccination of HIV-infected pregnant women: implications for protection of their young infants
por: Dangor, Ziyaad, et al.
Publicado: (2017)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis
por: Garrido, Hannah M.Garcia, et al.
Publicado: (2020)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)

Streptococcus pneumoniae and other bacterial nasopharyngeal colonization seven years post-introduction of 13-valent pneumococcal conjugate vaccine in South African children
por: Downs, Sarah L., et al.
Publicado: (2023)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence
por: Chilson, Erica, et al.
Publicado: (2020)

Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa
por: Koen, Anthonet, et al.
Publicado: (2020)

Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study
por: Mackenzie, Grant A., et al.
Publicado: (2022)

The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
por: Feldman, Charles, et al.
Publicado: (2020)

Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2021)

Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection
por: Dunne, Eileen M., et al.
Publicado: (2023)

Immunogenicity of tetanus, diphtheria and acellular pertussis vaccination among pregnant women living with and without HIV
por: Nunes, Marta C., et al.
Publicado: (2023)

COVID-19 vaccines in pregnancy
por: Nunes, Marta C., et al.
Publicado: (2022)

Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
por: Seo, Yu Bin, et al.
Publicado: (2017)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
por: Lee, Hyunju, et al.
Publicado: (2014)

Population genomics of pneumococcal carriage in South Africa following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) immunization
por: Javaid, Nida, et al.
Publicado: (2022)

Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Immunogenicity
por: Deloria Knoll, Maria, et al.
Publicado: (2014)

Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial
por: Nunes, Marta C, et al.
Publicado: (2020)

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
por: Platt, Heather L., et al.
Publicado: (2020)

Prevention of influenza-related illness in young infants by maternal vaccination during pregnancy
por: Nunes, Marta C, et al.
Publicado: (2018)

Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study
por: Lombardi, Francesca, et al.
Publicado: (2016)

Pneumococcal Conjugate Vaccine Safety in Elderly Adults
por: Tseng, Hung Fu, et al.
Publicado: (2018)

Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled Trial
por: Pomat, William S., et al.
Publicado: (2013)

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae
por: Turner, Allison E.B., et al.
Publicado: (2017)

Persistent High Burden of Invasive Pneumococcal Disease in South African HIV-Infected Adults in the Era of an Antiretroviral Treatment Program
por: Nunes, Marta C., et al.
Publicado: (2011)

Pneumococcal vaccination in persons living with HIV: Pneumococcal conjugate, polysaccharide or both?
por: Dhingra, Bhavna, et al.
Publicado: (2020)

Safety and Immunogenicity of Pneumococcal Conjugate Vaccines in a High-risk Population: A Randomized Controlled Trial of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine in Papua New Guinean Infants
por: Pomat, William S, et al.
Publicado: (2019)

Effect of HIV-exposure and timing of anti-retroviral treatment on immunogenicity of trivalent live-attenuated polio vaccine in infants
por: Moonsamy, Shelina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ldvv7uh87frjk219q6s5qquv0o